Sign inJoin waitlistJoin the waitlist

Samer Al-Homsi

Physician · Long Island Jewish Medical Center - Northwell Health

Credentials: · · · · · · · ·

History

Long Island Jewish Medical Center - Northwell Health
2024–Present

Hematology
1987–1988
Internal Medicine
1984–1987
Doctor of Medicine
1980–1984

Research

Phase I Trial of Anti-PSMA Designer CAR-T Cells in Prostate Cancer: Possible Role for Interacting Interleukin 2-T Cell Pharmacodynamics as a Determinant of Clinical Response
The Prostate · 2016 · 219 citations
Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A…
Transplantation and Cellular Therapy · 2021 · 172 citations
Post-transplant high-dose cyclophosphamide for the prevention of graft-versus-host disease
Biology of Blood and Marrow Transplantation · 2015 · First of 5 authors · Corresponding · 103 citations

Jean Yared
9 papers
BS
Bipin Savani
8 papers
Hillard Lazarus
8 papers
TN
Taiga Nishihori
8 papers
BW
Baldeep Wirk
7 papers
CF
Cesar Freytes
7 papers
Gerhard Hildebrandt
7 papers
SH
Shahrukh Hashmi
7 papers
Mohamed Dabaja
6 papers
Saurabh Chhabra
6 papers
Siddhartha Ganguly
6 papers
Usama Gergis
6 papers

Grants

Phase I/II Trial of Sitagliptin, Bortezomib and Post-Transplant Cyclophosphamide for GvHD Prophylaxis; IND 158327 (09/03/2021)
Food and Drug Administration · R01
Contact PI · $1.3M · Feinstein Institute for Medical Research
2023–2029
Research in the Pathogenesis of Hematologic Disorders
National Heart, Lung, and Blood Institute · T32
Contact PI · $703.1K · New York University School of Medicine
1975–2019

Clinical trials

High-Dose Post-Transplant Cyclophosphamide and Bortezomib (CyBor) for the Prevention of Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Principal investigator · Completed · Phase 2
NYU Langone Health
2019–2024